FDA approves Amyvid™
6 April 2012 | By Eli Lilly and Company
Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain...
List view / Grid view
News
FDA decides Teva is sole first-to-file on Provigil®
5 April 2012 | By Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil® (modafinil)...
Sanofi and Regeneron announce regulatory and clinical update for Zaltrap® (aflibercept)
5 April 2012 | By Sanofi
The FDA has granted Priority Review of the BLA for the investigational agent Zaltrap®...
BASF and Catalent join forces to solve bioavailability challenges
4 April 2012 | By Catalent Pharma Solutions
Catalent Pharma Solutions and BASF have entered into a broad collaboration...
UCB and Amgen initiate sclerostin antibody Phase 3 program in patients with Postmenopausal Osteoporosis
4 April 2012 | By Amgen
The start of sclerostin antibody Phase 3 clinical trial program announced...
Lonza appoints Richard Ridinger as new CEO
At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza. Mr. Ridinger will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.
Tecan granted patent for revolutionary NanoQuant Plate™
3 April 2012 | By kdm communications limited
The revolutionary design of Tecan’s NanoQuant Plate™ has been recognized with the granting of a new European patent...
A case study by Catalent expert to be presented at PDA Annual Meeting
3 April 2012 | By Catalent Pharma Solutions
“Challenging Technical Transfer of a Biopharmaceutical – the Product X Case Study”...
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
3 April 2012 | By GlaxoSmithKline
Data from seven studies support progression towards regulatory filings...
Interview with Robert Mattes, Applications Scientist, FOSS NIRSystems
2 April 2012 | By FOSS NIRSystems
Freddy White, European Pharmaceutical Review speaks to Robert Mattes, Applications Scientist, FOSS NIRSystems...
Gerresheimer grows in the emerging markets and acquires Indian pharma glass manufacturer Neutral Glass
2 April 2012 | By Gerresheimer AG
Gerresheimer AG, is committed to growth in the emerging markets...
Teva announces launch of generic Avapro® and generic Avalide® in the United States
2 April 2012 | By Teva Pharmaceutical Industries Ltd
180-day period of marketing exclusivity awarded...
Novartis QVA149 Phase III COPD studies meet primary endpoints
2 April 2012 | By Novartis
QVA149 efficacy, safety and exercise endurance primary endpoints all met[1],[2],[3]...
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
2 April 2012 | By GlaxoSmithKline
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
Efficacy and safety data for ZOSTAVAX®
2 April 2012 | By Merck
Merck announced that data from the pivotal Phase III study with ZOSTAVAX® in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases...
